Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2032

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 26

3.2 Scope Of Study 26

3.3 List Of Assumptions 26

3.4 Market Structure 27

4 Research Methodology

4.1 Research Process 29

4.2 Primary Research 30

4.3 Secondary Research 31

4.4 Market Size Estimation 32

4.5 Forecast Model 32

5 Market Dynamics

5.1 Introduction 34

5.2 Drivers 35

5.2.1 Increasing Preference For Minimally Invasive Procedures 35

5.2.2 Rising Prevalence Of Chronic Disorders 36

5.2.3 Improvement In Reimbursement Scenario 37

5.2.4 Rising Geriatric Population 38

5.3 Restraints 39

5.3.1 Rising Treatment Cost And Hospital Stay 39

5.3.2 Lack Of Skilled Physicians 40

5.4 Opportunities 41

5.4.1 New Advancements In Catheterization Devices 41

5.4.2 Guide Wire Assisted Surgery In Elderly Population 41

5.1 Mega Trends 41

5.1.1 Telemedicine 41

5.2 Macroeconomic Indicators 41

5.3 Technology Trends & Assessment 42

6 Market Factor Analysis

6.1 Porter’s Five Forces Model 44

6.1.1 Threat Of New Entrants 44

6.1.2 Bargaining Power Of Suppliers 44

6.1.3 Threat Of Substitutes 45

6.1.4 Bargaining Power Of Buyers 45

6.1.5 Intensity Of Rivalry 45

6.2 Supply Chain Analysis 46

6.2.1 Research &Development 46

6.2.2 Manufacturing 46

6.2.3 Distribution 46

6.2.4 Marketing & Sales 47

6.2.5 Post-Sales Monitoring 47

6.3 Demand & Supply: Gap Analysis 47

6.4 Pricing Analysis 47

6.5 Investment Feasibility Analysis 47

7 Global Transient Ischemic Attack Market, By Diagnosis

7.1 Introduction 49

7.2 Imaging Techniques 49

7.2.1 Computed Tomography (CT) Scan 51

7.2.2 Carotid Duplex Scanning 51

7.2.3 Magnetic Resonance Imaging 52

7.2.4 Echocardiography 52

8 Global Transient Ischemic Attack Market, By Treatment

8.1 Introduction 54

8.2 Surgery 54

8.3 Drugs 54

8.3.1 Surgery 55

8.3.2 Drugs 56

8.3.2.1 Antithrombotic Agents 56

8.3.2.2 Antiplatelets 56

8.3.2.3 Clopidogrel 57

8.3.2.4 Aspirin 57

8.3.2.5 Heparins 57

8.3.2.6 ENOXAPARIN 58

8.3.2.7 DALTEPARIN 58

8.3.2.8 Fibrinolytics 58

8.3.2.9 Tenecteplase 59

8.3.2.10 Alteplase 59

8.3.2.11 Antihypertensive Agents 59

8.3.2.12 Prazosin 60

8.3.2.13 Moxonidine 60

9 Global Transient Ischemic Attack Market, By Age Groups

9.1 Introduction 62

9.2 0–18 Years 62

9.3 19–40 Years (Millennial) 62

9.4 41–60 Years 62

9.5 60+ Years 63

9.5.1 0-18 Years 64

9.5.2 19-40 Years 65

9.5.3 41-60 Years 65

9.5.4 60+ Years 65

10 Global Transient Ischemic Attack Market, By End-User

10.1 Introduction 67

10.2 Hospitals & Clinics 67

10.3 Diagnostic Centers 67

10.4 Research Laboratories 68

10.4.1 Hospitals 69

10.4.2 Diagnostic Centers 70

10.4.3 Research Laboratories 70

11 Global Transient Ischemic Attack Market, By Region

11.1 Introduction 72

11.2 Americas 73

11.2.1 North America 78

11.2.1.1 U.S. 82

11.2.1.2 Canada 86

11.2.2 South America 90

11.3 Europe 94

11.3.1 Western Europe 99

11.3.1.1 Germany 103

11.3.1.2 France 107

11.3.1.3 U.K. 111

11.3.1.4 Italy 115

11.3.1.5 Spain 119

11.3.1.6 Rest Of Western Europe 123

11.3.2 Eastern Europe 127

11.4 Asia Pacific 131

11.4.1 Asia Pacific 132

11.4.2 Japan 136

11.4.3 China 140

11.4.4 India 144

11.4.5 Australia 148

11.4.6 Republic Of Korea 152

11.4.7 Rest Of Asia Pacific 156

11.5 The Middle East & Africa 160

11.5.1 Middle East And Africa 161

11.5.2 United Arab Emirates 164

11.5.3 Saudi Arabia 168

11.5.4 Rest Of Middle East & Africa 172

12 Competitive Landscape

12.1 Company Market Share Analysis 177

12.1.1 Introduction 177

12.2 Company Share Analysis 178

12.3 Recent Developments, 2013–2018 179

13 Company Profiles

13.1 Koninklijke Philips N.V. 184

13.1.1 Company Overview 184

13.1.2 Financial Overview 184

13.1.3 Products Offering 185

13.1.4 Key Developments 185

13.1.5 SWOT Analysis 185

13.1.6 Key Strategy 186

13.2 Stryker Corporation 187

13.2.1 Company Overview 187

13.2.2 Financial Overview 187

13.2.3 Products Offering 188

13.2.4 Key Developments 188

13.2.5 SWOT Analysis 189

13.2.6 Key Strategy 189

13.3 Johnson & Johnson Services Inc. 190

13.3.1 Company Overview 190

13.3.2 Financial Overview 190

13.3.3 Products Offering 191

13.3.4 Key Developments 191

13.3.5 SWOT Analysis 192

13.3.6 Key Strategy 192

13.4 Boston Scientific Corporation 193

13.4.1 Company Overview 193

13.4.2 Financial Overview 193

13.4.3 Products Offering 194

13.4.4 Key Developments 195

13.4.5 SWOT Analysis 195

13.4.6 Key Strategy 195

13.5 Sanofi 196

13.5.1 Company Overview 196

13.5.2 Financial Overview 196

13.5.3 Products Offering 197

13.5.4 Key Developments 197

13.5.5 SWOT Analysis 197

13.5.6 Key Strategy 197

13.6 Bayer AG 198

13.6.1 Company Overview 198

13.6.2 Financial Overview 198

13.6.3 Products Offering 199

13.6.4 Key Developments 199

13.6.5 SWOT Analysis 199

13.6.6 Key Strategy 199

13.7 Pfizer Inc. 200

13.7.1 Company Overview 200

13.7.2 Financial Overview 200

13.7.3 Products Offering 201

13.7.4 Key Developments 201

13.7.5 SWOT Analysis 201

13.7.6 Key Strategy 201

13.8 Siemens AG 202

13.8.1 Company Overview 202

13.8.2 Financial Overview 202

13.8.3 Products Offering 203

13.8.4 Key Developments 203

13.8.5 SWOT Analysis 203

13.8.6 Key Strategy 203

13.9 F. Hoffmann-La Roche AG 204

13.9.1 Company Overview 204

13.9.2 Financial Overview 204

13.9.3 Products Offering 205

13.9.4 Key Developments 205

13.9.5 SWOT Analysis 205

13.9.6 Key Strategy 205

13.10 GE Healthcare 206

13.10.1 Company Overview 206

13.10.2 Financial Overview 206

13.10.3 Products Offering 207

13.10.4 Key Developments 207

13.10.5 SWOT Analysis 207

13.10.6 Key Strategy 207

13.11 Penumbra, Inc. 208

13.11.1 Company Overview 208

13.11.2 Financial Overview 208

13.11.3 Products Offering 209

13.11.4 Key Developments 209

13.11.5 SWOT Analysis 209

13.11.6 Key Strategy 210

13.12 Medtronic PLC 211

13.12.1 Company Overview 211

13.12.2 Financial Overview 211

13.12.3 Products Offering 212

13.12.4 Key Developments 212

13.12.5 SWOT Analysis 212

13.12.6 Key Strategy 213

13.13 Abbott Laboratories 214

13.13.1 Company Overview 214

13.13.2 Financial Overview 214

13.13.3 Products Offering 215

13.13.4 Key Developments 215

13.13.5 SWOT Analysis 216

13.13.6 Key Strategy 216

13.14 Merck & Co., Inc. 217

13.14.1 Company Overview 217

13.14.2 Financial Overview 217

13.14.3 Products Offering 218

13.14.4 Key Developments 218

13.14.5 SWOT Analysis 218

13.14.6 Key Strategy 218

13.15 Boehringer Ingelheim GmbH 219

13.15.1 Company Overview 219

13.15.2 Financial Overview 219

13.15.3 Products Offering 220

13.15.4 Key Developments 220

13.15.5 SWOT Analysis 220

13.15.6 Key Strategy 220

14 Conclusion

14.1 Key Findings 222

14.1.1 CEO’s Viewpoint 222

14.1.2 Unmet Needs 222

14.1.3 Key Companies To Watch 222

14.1.4 Prediction 222

15 Appendix

15.1 Discussion Blue Print 224

15.2 References 225

16 List Of Tables

TABLE 1 MARKET SYNOPSIS 24

TABLE 2 LIST OF ASSUMPTIONS 26

TABLE 3 PRIMARY INTERVIEWS 30

TABLE 4 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50

TABLE 5 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027 (USD MILLION) 50

TABLE 6 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,

2020–2027 (USD MILLION) 51

TABLE 7 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,

2020–2027 (USD MILLION) 51

TABLE 8 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,

2020–2027 (USD MILLION) 52

TABLE 9 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY ECHOCARDIOGRAPHY,

2020–2027 (USD MILLION) 52

TABLE 10 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 11 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY SURGERY, 2020–2027 (USD MILLION) 55

TABLE 12 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56

TABLE 13 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUG, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 56

TABLE 14 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 56

TABLE 15 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57

TABLE 16 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION) 57

TABLE 17 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57

TABLE 18 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD MILLION) 58

TABLE 19 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY DALTEPARIN, 2020–2027 (USD MILLION) 58

TABLE 20 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 58

TABLE 21 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59

TABLE 22 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027 (USD MILLION) 59

TABLE 23 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59

TABLE 24 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,

2020–2027 (USD MILLION) 60

TABLE 25 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,

2020–2027 (USD MILLION) 60

TABLE 26 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020–2027 (USD MILLION) 63

TABLE 27 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION) 64

TABLE 28 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 19-40 YEARS, 2020–2027 (USD MILLION) 65

TABLE 29 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION) 65

TABLE 30 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 60+ YEARS, 2020–2027 (USD MILLION) 65

TABLE 31 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68

TABLE 32 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 69

TABLE 33 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70

TABLE 34 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 70

TABLE 35 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 72

TABLE 36 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73

TABLE 37 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 74

TABLE 38 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74

TABLE 39 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 74

TABLE 40 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 75

TABLE 41 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 75

TABLE 42 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 75

TABLE 43 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 76

TABLE 44 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 76

TABLE 45 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76

TABLE 46 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 77

TABLE 47 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 77

TABLE 48 NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 49 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 78

TABLE 50 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 79

TABLE 51 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 52 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79

TABLE 53 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 80

TABLE 54 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 80

TABLE 55 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 80

TABLE 56 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 81

TABLE 57 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 81

TABLE 58 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81

TABLE 59 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 82

TABLE 60 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 82

TABLE 61 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82

TABLE 62 U.S. TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 83

TABLE 63 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 83

TABLE 64 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 83

TABLE 65 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 84

TABLE 66 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 84

TABLE 67 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 84

TABLE 68 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85

TABLE 69 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 85

TABLE 70 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 85

TABLE 71 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86

TABLE 72 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 86

TABLE 73 CANADA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 86

TABLE 74 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87

TABLE 75 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 87

TABLE 76 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 87

TABLE 77 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88

TABLE 78 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 88

TABLE 79 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 88

TABLE 80 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 89

TABLE 81 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 89

TABLE 82 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90

TABLE 83 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 90

TABLE 84 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 90

TABLE 85 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 91

TABLE 86 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 91

TABLE 87 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 91

TABLE 88 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 92

TABLE 89 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 92

TABLE 90 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 92

TABLE 91 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93

TABLE 92 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 93

TABLE 93 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94

TABLE 94 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95

TABLE 95 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 95

TABLE 96 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 95

TABLE 97 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96

TABLE 98 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 96

TABLE 99 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 96

TABLE 100 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97

TABLE 101 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 97

TABLE 102 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 97

TABLE 103 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 98

TABLE 104 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 98

TABLE 105 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99

TABLE 106 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 99

TABLE 107 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 99

TABLE 108 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 100

TABLE 109 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 100

TABLE 110 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 100

TABLE 111 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 101

TABLE 112 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 101

TABLE 113 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 101

TABLE 114 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 102

TABLE 115 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 102

TABLE 116 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103

TABLE 117 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 103

TABLE 118 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103

TABLE 119 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 104

TABLE 120 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104

TABLE 121 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 104

TABLE 122 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 105

TABLE 123 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 105

TABLE 124 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105

TABLE 125 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 106

TABLE 126 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 106

TABLE 127 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107

TABLE 128 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 107

TABLE 129 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107

TABLE 130 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 108

TABLE 131 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108

TABLE 132 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 108

TABLE 133 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 109

TABLE 134 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 109

TABLE 135 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 109

TABLE 136 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110

TABLE 137 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 110

TABLE 138 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 111

TABLE 139 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 111

TABLE 140 U.K TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 111

TABLE 141 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112

TABLE 142 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 112

TABLE 143 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112

TABLE 144 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 113

TABLE 145 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 113

TABLE 146 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 113

TABLE 147 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114

TABLE 148 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 114

TABLE 149 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 115

TABLE 150 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115

TABLE 151 ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 115

TABLE 152 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 116

TABLE 153 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 116

TABLE 154 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 116

TABLE 155 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 117

TABLE 156 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 117

TABLE 157 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117

TABLE 158 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 118

TABLE 159 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 118

TABLE 160 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 119

TABLE 161 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 119

TABLE 162 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 119

TABLE 163 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120

TABLE 164 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 120

TABLE 165 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 120

TABLE 166 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121

TABLE 167 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 121

TABLE 168 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 121

TABLE 169 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 122

TABLE 170 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 122

TABLE 171 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 123

TABLE 172 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 123

TABLE 173 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 123

TABLE 174 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124

TABLE 175 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 124

TABLE 176 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 124

TABLE 177 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 125

TABLE 178 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 125

TABLE 179 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 125

TABLE 180 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 126

TABLE 181 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 126

TABLE 182 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 127

TABLE 183 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 127

TABLE 184 EASTERN EUROPE TRANSIENT ISCHE